Intuitive Surgical, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Intuitive Surgical, Inc. stock analysis ISRG overview
Bullish +75

How Strong Q1 2026 Results and Completed Buyback Will Impact Intuitive Surgical (ISRG) Investors

📈 Intuitive Surgical (ISRG) reported Q1 2026 non-GAAP EPS of $2.50, beating the $2.11 analyst consensus.

💰 Revenue reached $2.77 billion, representing a 23% year-over-year increase driven by strong adoption of da Vinci systems.

🤖 The company placed 431 new da Vinci systems, including 232 units of the newer da Vinci 5 platform in its installed base.

📉 Shares are currently trading at a 20% discount to their 52-week high following a 15% decline over the last year.

🤲 Analysts recommend ISRG as a buying opportunity, with a price target of $615.93 implying roughly 28% upside.

🔍 da Vinci 5 utilization in the U.S. has grown by 4%, exceeding the performance metrics of the previous Xi generation.

🧬 Advanced procedure types like Single Port surgeries grew 68% year-over-year, bolstered by positive clinical studies.

⚠️ Bearish concerns focus on valuation multiples, with the stock trading at a P/E ratio of 58 and potential deceleration in growth.

🌍 External headwinds include tariffs on components from Mexico, Germany, and China adding approximately 1% revenue drag.

💊 The GLP-1 obesity drug trend has negatively impacted bariatrics procedures, causing a decline in that specific segment of 10%.

📉 Insider activity shows net selling, though analysts suggest this is largely attributable to scheduled stock vesting.

✅ Gross margins expanded to 67.8%, with da Vinci 5 contribution margins becoming comparable to the older Xi model.

🎯 A bull case scenario projects a total return of 34.6% if placements stay above 230 per quarter and tariffs remain stable.

📉 A bear case analysis suggests a lower price target of $546.67, which is still above the current stock price.

🔮 Long-term projections assume mid-teens procedure growth through 2030 alongside modest compression in valuation multiples.

💹 Continued buyback programs and high-quality compounder characteristics support the thesis despite recent volatility.

Bullish Signals
  • Intuitive Surgical delivered Q1 non-GAAP EPS of $2.50, beating the consensus estimate of $2.11 and marking four straight quarters of EPS beats.
  • Revenue surged 23% year-over-year to $2.77 billion, demonstrating robust demand despite market headwinds.
  • The company placed 431 da Vinci systems in the quarter, with 232 da Vinci 5 units now contributing to a growing installed base of 1,500 systems.
  • da Vinci 5 adoption is accelerating, driving U.S. utilization growth of 4%, which exceeds the performance of the legacy da Vinci Xi model.
  • Single Port procedures grew impressively by 68% year-over-year, while Ion procedures climbed 39%, bolstered by a Mayo Clinic study showing 79% diagnostic yield.
  • Gross margins expanded to 67.8%, and da Vinci 5 contribution margins have become comparable with the older Xi platform, indicating strong operating leverage.
  • Analysts see Intuitive Surgical trading at a 20% discount to its 52-week high, creating a potential buying opportunity with a price target of $615.93 implying 28% upside.
  • The stock has shown recent stabilization, gaining 2.77% over the past week following the strong Q1 earnings print on April 21.
Risk Factors
  • The stock is down 5.1% over the past year and trades 20% below its 52-week high, indicating recent bearish sentiment despite strong quarterly results.
  • Procedure growth is projected to decelerate from 18% in 2025 to between 13.5% and 15.5% in 2026, raising concerns about slowing top-line expansion.
  • Tariffs on sourcing from Mexico, Germany, and China are expected to add roughly 1% revenue drag, negatively impacting margins.
  • The adoption of GLP-1 medications has pulled bariatrics procedures down 10%, creating a specific headwind for that therapeutic area.
  • China faces policy-driven pricing pressure which could suppress revenue from that market.
  • Insider activity has shown net selling, although analysts attribute this largely to scheduled vesting rather than lack of confidence.
  • The setup weakens if procedure growth slips below 13% or if hospital capital expenditure tightens materially.
  • Future earnings projections are uncertain as international ramp-up for da Vinci 5 and telesurgery commercialization remain key variables.
Full Analysis
Intuitive Surgical (ISRG) reported strong Q1 2026 non-GAAP earnings, posting EPS of $2.50 against a consensus of $2.11, while revenue reached $2.77 billion, representing a 23% year-over-year increase. The company successfully placed 431 new da Vinci robotic systems during the quarter, including 232 units of the newer da Vinci 5 platform. This latest generation has expanded the installed base to 1,500 systems and is credited with driving a 4% U.S. utilization growth rate that exceeds that of the prior da Vinci Xi model. The company posted its fourth consecutive earnings beat, supported by a 47.95% jump in operating income and an expansion of gross margins to 67.8%. Despite these operational strengths, shares of ISRG have declined roughly 15% year-over-year and trade at a 20% discount to their 52-week high of $603.88, hovering around $482.22 as of the latest report on April 21. Analysts from 24/7 Wall St. view this price action as a potential buying opportunity, setting a price target of $615.93 which implies approximately 28% upside over the next 12 months. The bullish case relies heavily on sustained da Vinci 5 adoption, with Bulls projecting a bull-case price of $649.08 if quarterly placements remain above 230 units. Growth is further supported by single-port procedures surging 68% year-over-year and Ion procedure volumes climbing 39%, bolstered by positive clinical data from Mayo Clinic showing a 79% diagnostic yield for lung lesion biopsies. However, significant headwinds and valuation concerns persist in the bear case. Intuitive Surgical currently trades at a P/E ratio of 58 and an EV/EBITDA multiple of 42, with analysts warning that procedure growth is expected to decelerate from 18% in 2025 to between 13.5% and 15.5% in 2026. Additional risks include approximately 1% revenue drag from tariffs on sourcing from Mexico, Germany, and China, a 10% decline in the bariatrics segment due to GLP-1 adoption, and policy-driven pricing pressure in China. Insider activity has shown net selling, though analysts note this is largely attributable to scheduled vesting rather than lack of confidence. Even under bearish scenarios, the estimated price target remains at $546.67, which is still above current trading levels. The investment thesis centers on ISRG's status as a high-quality compounder that is trading significantly below its recent highs while maintaining robust revenue growth. The bull case remains intact provided da Vinci 5 placements continue to exceed expectations and the tariff impact stays contained at roughly 1%, though the setup could weaken if procedure growth slips below 13% or if hospital capital expenditure tightens materially. Long-term outlooks for 2027 through 2029 are not explicitly modeled but rely on assumptions of mid-teens procedure growth, modest multiple compression, and ongoing share buybacks to support shareholder returns.